CYTK Aficamten data support FDA submission in non-obstructive HCM
CYTK says Aficamten showed significant, broad clinical benefit and safety in non-obstructive HCM, supporting an FDA submission.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.